ANKIAL Pharma

ANKIAL Pharma is a biotech-Pharma start-up company that is developing a drug to treat hypertrophic cardiomyopathy (HCM), a heart disease that affects 20 million patients worldwide. The drug ANK0121 (patented by INSERM/Bordeaux Hospital and University) acts on mitochondria, the powerplant of the heart. This technology promotes mitochondrial recycling to improve heart bioenergetics and prevent hypertrophic cardiomyopathy in various in vivo models of HCM. ANKIAL operates from the preclinical phase to the marketing authorization. The team includes 5 founders. The CEO Bruno LEGRAND has 25 years of expertise in the pharmaceutical industry sector (cardio-metabolic drugs), the CSO Rodrigue ROSSIGNOL is an international expert in mitochondrial pharmacology, the CMO Didier LACOMBE is a member of the Academy of Medicine and has directed clinical trials, and the CFO Vincent BENOIS is a certified accountant/auditor; he defines the financial strategy of many biotech pharma companies. Our ANK0121 technology is patented, formulated and tested in vivo and its usability is validated. Current stage of ANKIAL is fund raising to advance regulatory toxicity analysis and complete the IND request.